Chronic myeloid leukemia in 2007

Journal of Managed Care Pharmacy

Volumn 13, Issue 8 SUPPL. A, 2007, Pages

  Sessions, Jolynn ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

BCR ABL; Chronic myeloid leukemia; Cytogenetics; Fluorescence in situ hybridization; Polymerase chain reaction

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INTERFERON; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN;

BLOOD CELL COUNT; CARCINOGENESIS; CELL DIVISION; CELL FUNCTION; CELL GROWTH; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE COURSE; DOWNSTREAM PROCESSING; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH CARE COST; HUMAN; LABORATORY TEST; LEUKEMIA CELL; MOLECULAR BIOLOGY; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVIEW; THROMBOCYTE COUNT; TREATMENT FAILURE;

EID: 36248942654     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s8-a.4     Document Type: Review

References (12)

1. American Cancer Society. Cancer facts and figures 2007. Available at: www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. Accessed February 2, 2007.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-40.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
4. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25:49-61.
5. Savage DG, Szydlo RM, Chase A, et al. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol. 1997;99:30-35.
6. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207-19.
7. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (World Health Organization Classification of Tumors). Vol. 3. Lyon, France: IARC Press; 2001.
8. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. V.II.2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/ cml.pdf. Accessed May 14, 2007.
9. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497.
10. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375-84.
11. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-17.
12. Tefferi A, Dewald GW, Litzow ML, et al. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc. 2005;80:390-402.